LYON, France, June 18, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it received CE Mark (European regulatory approval) for Focal.One ® , its new and innovative robotic HIFU device fully dedicated to focal therapy of prostate cancer. Focal.One was showcased as world premiere at the European Urology Association Congress in Milan, Italy on March 15-19, 2013. Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "This is a significant regulatory achievement and a key milestone as we received EU market clearance for the first robotic HIFU device dedicated to a focal targeted treatment approach. This CE mark positions Focal.One for full commercialization in Europe and in many other countries. It confirms EDAP's expertise in managing R&D and regulatory programs successfully. I wish to deeply congratulate the EDAP team for their extraordinary efforts in bringing Focal.One to market in a timely manner." Mr. Oczachowski continued, "Utilizing a focal therapy approach to target the cancer cells within the prostate gland for the treatment of prostate cancer is gaining wider acceptance across the international urological community. Combining into one unique HIFU device the latest imaging modalities, such as MRI localization and contrast-enhanced ultrasound control, with the ultimate dynamic focusing HIFU technology, Focal.One will offer an optimal focal therapy of prostate cancer while preserving patient quality of life." Focal.One is the first device fully dedicated to the focal approach for prostate cancer therapy. It combines the three essential components to efficiently perform a focal treatment: (i) state-of-the-art imaging to localize tumors with the use of magnetic resonance imaging (MRI) combined with real-time ultrasound, (ii) utmost precision of HIFU treatment focused on identified targeted cancer areas only and (iii) immediate feedback on treatment efficacy utilizing Contrast-Enhanced Ultrasound Imaging. EDAP's unique and exclusive range of HIFU products, including Ablatherm Integrated Imaging and Focal.One, has now the capacity to offer a wide array of treatment options to patients with prostate cancer.